PCM
Parsons Capital Management’s Relmada Therapeutics RLMD Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $98.1K | Hold |
163,336
| – | – | 0.01% | 436 |
|
|
2025
Q1 | $44.1K | Hold |
163,336
| – | – | ﹤0.01% | 430 |
|
|
2024
Q4 | $84.9K | Sell |
163,336
-839,359
| -84% | -$436K | ﹤0.01% | 435 |
|
|
2024
Q3 | $3.25M | Buy |
1,002,695
+26,750
| +3% | +$86.7K | 0.21% | 112 |
|
|
2024
Q2 | $2.93M | Buy |
975,945
+2,425
| +0.2% | +$7.28K | 0.2% | 114 |
|
|
2024
Q1 | $4.53M | Buy |
973,520
+23,679
| +2% | +$110K | 0.31% | 77 |
|
|
2023
Q4 | $3.93M | Sell |
949,841
-24,241
| -2% | -$100K | 0.28% | 85 |
|
|
2023
Q3 | $2.92M | Buy |
974,082
+100,770
| +12% | +$302K | 0.23% | 93 |
|
|
2023
Q2 | $2.15M | Buy |
873,312
+151,146
| +21% | +$372K | 0.16% | 127 |
|
|
2023
Q1 | $1.63M | Buy |
722,166
+225,912
| +46% | +$511K | 0.13% | 158 |
|
|
2022
Q4 | $1.73M | Sell |
496,254
-7,547
| -1% | -$26.3K | 0.14% | 143 |
|
|
2022
Q3 | $18.7M | Buy |
503,801
+25
| +0% | +$926 | 1.67% | 9 |
|
|
2022
Q2 | $9.57M | Buy |
503,776
+700
| +0.1% | +$13.3K | 0.86% | 21 |
|
|
2022
Q1 | $13.6M | Sell |
503,076
-336
| -0.1% | -$9.07K | 1.03% | 17 |
|
|
2021
Q4 | $11.3M | Buy |
503,412
+30,438
| +6% | +$686K | 0.81% | 22 |
|
|
2021
Q3 | $12.4M | Buy |
472,974
+22,562
| +5% | +$591K | 0.97% | 18 |
|
|
2021
Q2 | $14.4M | Sell |
450,412
-1,000
| -0.2% | -$32K | 1.1% | 12 |
|
|
2021
Q1 | $15.9M | Sell |
451,412
-200
| -0% | -$7.04K | 1.3% | 10 |
|
|
2020
Q4 | $14.5M | Sell |
451,612
-3,525
| -0.8% | -$113K | 1.25% | 11 |
|
|
2020
Q3 | $17.1M | Buy |
455,137
+1,050
| +0.2% | +$39.5K | 1.67% | 7 |
|
|
2020
Q2 | $20.3M | Buy |
454,087
+28,512
| +7% | +$1.28M | 2.16% | 6 |
|
|
2020
Q1 | $14.5M | Buy |
425,575
+58,642
| +16% | +$2M | 1.87% | 7 |
|
|
2019
Q4 | $14.3M | Buy |
+366,933
| New | +$14.3M | 1.44% | 11 |
|